Amylyx Pharmaceuticals (NASDAQ: AMLX) Confirmed on the August 6, 2026 Q2 2026 Earnings Call That Top-Line Data From the Pivotal Phase 3 LUCIDITY Trial of Avexitide (Exendin 9-39, a Peptide GLP-1 Receptor Antagonist) for Post-Bariatric Hypoglycemia Will Read Out in Late August or Early September 2026, One of the Most-Watched Near-Term Peptide-Specific Clinical Catalysts; Post-Bariatric Hypoglycemia Is a Serious Complication of Roux-en-Y Gastric Bypass Surgery That Affects Roughly 8% of Patients Long-Term and Manifests as Postprandial Hypoglycemia Driven by Excessive GLP-1 Signaling in the Reconfigured GI Anatomy; Avexitide (Formerly XOMA 358) Blocks GLP-1 Receptor Activation to Normalize Postprandial Glucose; Amylyx Q2 2026 EPS of -$0.39 Missed the -$0.35 Consensus by $0.04 (11% Below Forecast)
Amylyx Pharmaceuticals (NASDAQ: AMLX) confirmed on the August 6, 2026 Q2 2026 earnings call that top-line data from the registrational Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia will read out in late August or early September 2026. Avexitide (formerly XOMA 358) is exendin (9-39), a peptide GLP-1 receptor antagonist: a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking endogenous GLP-1 signaling. This is the mechanistic opposite of semaglutide, tirzepatide, and the other GLP-1 receptor agonists. Post-bariatric hypoglycemia (PBH) is a serious complication of Roux-en-Y gastric bypass surgery affecting roughly 8% of patients long-term and manifesting as postprandial hypoglycemia (dangerously low blood sugar after meals) driven by excessive GLP-1 signaling in the reconfigured GI anatomy. Avexitide blocks GLP-1 receptor activation to normalize postprandial glucose. Q2 2026 EPS of -$0.39 missed the -$0.35 consensus by $0.04 (11% below forecast). The LUCIDITY readout is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism. If positive, avexitide would represent a first-in-class approved therapy for post-bariatric hypoglycemia, an indication with no currently approved drug therapy.